MovDisordV3, Main, Exploration, bibRecord, 001930

Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

Identifieur interne : 001930 ( Main/Exploration ); précédent : 001929; suivant : 001931

Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

Auteurs : Matthew Menza [États-Unis] ; Roseanne Defronzo Dobkin [États-Unis] ; Humberto Marin [États-Unis] ; Michael Gara [États-Unis] ; Karina Bienfait [États-Unis] ; Allison Dicke [États-Unis] ; Cynthia L. Comella [États-Unis] ; Charles Cantor [États-Unis] ; Lee Hyer [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-08-15.

RBID : ISTEX:AF481A81AEA587E5904C0A184C7F636BBAE2B67A

Descripteurs français

Pascal (Inist)
- Eszopiclone, Insomnie, Maladie de Parkinson, Pathologie du système nerveux, Placebo, Traitement.

English descriptors

KwdEn :
- Adult, Aged, Aged, 80 and over, Azabicyclo Compounds (therapeutic use), Double-Blind Method, Eszopiclone, Female, Humans, Hypnotics and Sedatives (therapeutic use), Insomnia, Male, Middle Aged, Nervous system diseases, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Piperazines (therapeutic use), Placebo, Sleep Initiation and Maintenance Disorders (drug therapy), Sleep Initiation and Maintenance Disorders (etiology), Time Factors, Treatment, Treatment Outcome, insomnia, treatment.
MESH :
- chemical , therapeutic use : Azabicyclo Compounds, Hypnotics and Sedatives, Piperazines.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Sleep Initiation and Maintenance Disorders.
- etiology : Sleep Initiation and Maintenance Disorders.
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Time Factors, Treatment Outcome.

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being common and important, there are few data to guide clinical care. We conducted a 6‐week, randomized, controlled trial of eszopiclone and placebo in 30 patients with PD and insomnia. Patients with other primary sleep disorders (PSG defined) were excluded. The primary outcome was total sleep time (TST), and secondary measures included wake after sleep onset (WASO), number of awakenings, and quality of sleep, among others. The groups did not significantly differ on TST, but significant differences, favoring eszopiclone, did emerge in number of awakenings (P = 0.035), quality of sleep (P = 0.018), and in physician‐rated CGI improvement (P = 0.035). There was also a trend toward significance in WASO (P = 0.071). There were no significant differences between groups in measures of daytime functioning. The drug was well tolerated, with 33% of patients on eszopiclone and 27% of patients on placebo reporting adverse events. Although modest in size, this is the first controlled study of the treatment of insomnia in patients with PD. Eszopiclone did not increase TST significantly but was superior to placebo in improving quality of sleep and some measures of sleep maintenance, which is the most common sleep difficulty experienced by patients with PD. Definitive trials of the treatment of sleep disorders in this population are warranted. © 2010 Movement Disorder Society

Url:

DOI: 10.1002/mds.23168

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo</title>
<author><name sortKey="Menza, Matthew" sort="Menza, Matthew" uniqKey="Menza M" first="Matthew" last="Menza">Matthew Menza</name>
</author>
<author><name sortKey="Dobkin, Roseanne Defronzo" sort="Dobkin, Roseanne Defronzo" uniqKey="Dobkin R" first="Roseanne Defronzo" last="Dobkin">Roseanne Defronzo Dobkin</name>
</author>
<author><name sortKey="Marin, Humberto" sort="Marin, Humberto" uniqKey="Marin H" first="Humberto" last="Marin">Humberto Marin</name>
</author>
<author><name sortKey="Gara, Michael" sort="Gara, Michael" uniqKey="Gara M" first="Michael" last="Gara">Michael Gara</name>
</author>
<author><name sortKey="Bienfait, Karina" sort="Bienfait, Karina" uniqKey="Bienfait K" first="Karina" last="Bienfait">Karina Bienfait</name>
</author>
<author><name sortKey="Dicke, Allison" sort="Dicke, Allison" uniqKey="Dicke A" first="Allison" last="Dicke">Allison Dicke</name>
</author>
<author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
</author>
<author><name sortKey="Cantor, Charles" sort="Cantor, Charles" uniqKey="Cantor C" first="Charles" last="Cantor">Charles Cantor</name>
</author>
<author><name sortKey="Hyer, Lee" sort="Hyer, Lee" uniqKey="Hyer L" first="Lee" last="Hyer">Lee Hyer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:AF481A81AEA587E5904C0A184C7F636BBAE2B67A</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23168</idno>
<idno type="url">https://api.istex.fr/document/AF481A81AEA587E5904C0A184C7F636BBAE2B67A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000598</idno>
<idno type="wicri:Area/Istex/Curation">000598</idno>
<idno type="wicri:Area/Istex/Checkpoint">000609</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Menza M:treatment:of:insomnia</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928867</idno>
<idno type="RBID">PMC:2928867</idno>
<idno type="wicri:Area/Pmc/Corpus">000094</idno>
<idno type="wicri:Area/Pmc/Curation">000094</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000295</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001781</idno>
<idno type="wicri:Area/PubMed/Curation">001781</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001537</idno>
<idno type="wicri:Area/Ncbi/Merge">002C36</idno>
<idno type="wicri:Area/Ncbi/Curation">002C36</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002C36</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Menza M:treatment:of:insomnia</idno>
<idno type="wicri:Area/Main/Merge">001D66</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0413294</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000945</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002374</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000770</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Menza M:treatment:of:insomnia</idno>
<idno type="wicri:Area/Main/Merge">002357</idno>
<idno type="wicri:Area/Main/Curation">001930</idno>
<idno type="wicri:Area/Main/Exploration">001930</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo</title>
<author><name sortKey="Menza, Matthew" sort="Menza, Matthew" uniqKey="Menza M" first="Matthew" last="Menza">Matthew Menza</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UMDNJ‐University Behavioral Healthcare, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dobkin, Roseanne Defronzo" sort="Dobkin, Roseanne Defronzo" uniqKey="Dobkin R" first="Roseanne Defronzo" last="Dobkin">Roseanne Defronzo Dobkin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marin, Humberto" sort="Marin, Humberto" uniqKey="Marin H" first="Humberto" last="Marin">Humberto Marin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UMDNJ‐University Behavioral Healthcare, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gara, Michael" sort="Gara, Michael" uniqKey="Gara M" first="Michael" last="Gara">Michael Gara</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>UMDNJ‐University Behavioral Healthcare, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bienfait, Karina" sort="Bienfait, Karina" uniqKey="Bienfait K" first="Karina" last="Bienfait">Karina Bienfait</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dicke, Allison" sort="Dicke, Allison" uniqKey="Dicke A" first="Allison" last="Dicke">Allison Dicke</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Cantor, Charles" sort="Cantor, Charles" uniqKey="Cantor C" first="Charles" last="Cantor">Charles Cantor</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hyer, Lee" sort="Hyer, Lee" uniqKey="Hyer L" first="Lee" last="Hyer">Lee Hyer</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Medical College of Georgia, Augusta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-08-15">2010-08-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1708">1708</biblScope>
<biblScope unit="page" to="1714">1714</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">AF481A81AEA587E5904C0A184C7F636BBAE2B67A</idno>
<idno type="DOI">10.1002/mds.23168</idno>
<idno type="ArticleID">MDS23168</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Azabicyclo Compounds (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Eszopiclone</term>
<term>Female</term>
<term>Humans</term>
<term>Hypnotics and Sedatives (therapeutic use)</term>
<term>Insomnia</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Piperazines (therapeutic use)</term>
<term>Placebo</term>
<term>Sleep Initiation and Maintenance Disorders (drug therapy)</term>
<term>Sleep Initiation and Maintenance Disorders (etiology)</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>insomnia</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azabicyclo Compounds</term>
<term>Hypnotics and Sedatives</term>
<term>Piperazines</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
<term>Sleep Initiation and Maintenance Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sleep Initiation and Maintenance Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Eszopiclone</term>
<term>Insomnie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Placebo</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being common and important, there are few data to guide clinical care. We conducted a 6‐week, randomized, controlled trial of eszopiclone and placebo in 30 patients with PD and insomnia. Patients with other primary sleep disorders (PSG defined) were excluded. The primary outcome was total sleep time (TST), and secondary measures included wake after sleep onset (WASO), number of awakenings, and quality of sleep, among others. The groups did not significantly differ on TST, but significant differences, favoring eszopiclone, did emerge in number of awakenings (P = 0.035), quality of sleep (P = 0.018), and in physician‐rated CGI improvement (P = 0.035). There was also a trend toward significance in WASO (P = 0.071). There were no significant differences between groups in measures of daytime functioning. The drug was well tolerated, with 33% of patients on eszopiclone and 27% of patients on placebo reporting adverse events. Although modest in size, this is the first controlled study of the treatment of insomnia in patients with PD. Eszopiclone did not increase TST significantly but was superior to placebo in improving quality of sleep and some measures of sleep maintenance, which is the most common sleep difficulty experienced by patients with PD. Definitive trials of the treatment of sleep disorders in this population are warranted. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Géorgie (États-Unis)</li>
<li>Illinois</li>
<li>New Jersey</li>
<li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="New Jersey"><name sortKey="Menza, Matthew" sort="Menza, Matthew" uniqKey="Menza M" first="Matthew" last="Menza">Matthew Menza</name>
</region>
<name sortKey="Bienfait, Karina" sort="Bienfait, Karina" uniqKey="Bienfait K" first="Karina" last="Bienfait">Karina Bienfait</name>
<name sortKey="Cantor, Charles" sort="Cantor, Charles" uniqKey="Cantor C" first="Charles" last="Cantor">Charles Cantor</name>
<name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name>
<name sortKey="Dicke, Allison" sort="Dicke, Allison" uniqKey="Dicke A" first="Allison" last="Dicke">Allison Dicke</name>
<name sortKey="Dobkin, Roseanne Defronzo" sort="Dobkin, Roseanne Defronzo" uniqKey="Dobkin R" first="Roseanne Defronzo" last="Dobkin">Roseanne Defronzo Dobkin</name>
<name sortKey="Gara, Michael" sort="Gara, Michael" uniqKey="Gara M" first="Michael" last="Gara">Michael Gara</name>
<name sortKey="Gara, Michael" sort="Gara, Michael" uniqKey="Gara M" first="Michael" last="Gara">Michael Gara</name>
<name sortKey="Hyer, Lee" sort="Hyer, Lee" uniqKey="Hyer L" first="Lee" last="Hyer">Lee Hyer</name>
<name sortKey="Marin, Humberto" sort="Marin, Humberto" uniqKey="Marin H" first="Humberto" last="Marin">Humberto Marin</name>
<name sortKey="Marin, Humberto" sort="Marin, Humberto" uniqKey="Marin H" first="Humberto" last="Marin">Humberto Marin</name>
<name sortKey="Menza, Matthew" sort="Menza, Matthew" uniqKey="Menza M" first="Matthew" last="Menza">Matthew Menza</name>
<name sortKey="Menza, Matthew" sort="Menza, Matthew" uniqKey="Menza M" first="Matthew" last="Menza">Matthew Menza</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001930 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001930 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:AF481A81AEA587E5904C0A184C7F636BBAE2B67A
   |texte=   Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone and placebo

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.